GLMD earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E -0.25. Updated 2026-07-23.
Galmed Pharmaceuticals (GLMD) Research Hub
Galmed Pharmaceuticals (GLMD) trades on NASDAQ, IL in the Healthcare (Biotechnology) sector. As of 2026-09-09, shares last closed at 4.63 USD (+20.89%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.25, market cap 0.00B. This hub links to the full technical, earnings and options research available for GLMD.
Last updated 2026-09-09 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, IL |
| Last close | 4.63 USD (+20.89%) |
| 52-week range | 3.66 USD – 5.45 USD |
| Trend regime | Range |
| 14-day RSI | 47.5 (Neutral) |
| Trailing P/E | -0.25 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for GLMD
Covered Call on GLMD: how it works, illustrative setup around the real 4.63 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GLMD: how it works, illustrative setup around the real 4.63 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GLMD: how it works, illustrative setup around the real 4.63 USD price, max profit/loss, breakeven and when to use it. Educational.
GLMD technical analysis: range, last 4.63 USD, RSI 47.5, 52w range 3.66 USD–5.45 USD, real support/resistance. Updated 2026-09-09.
Frequently asked questions
What sector is GLMD in?
Galmed Pharmaceuticals (GLMD) is classified under Healthcare (Biotechnology), listed on NASDAQ, IL.
Is GLMD in an uptrend or downtrend?
As of 2026-09-09, GLMD is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GLMD's trailing P/E ratio?
GLMD's trailing P/E is -0.25, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does GLMD next report earnings?
GLMD is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of -0.39 USD.